☆ 4.4 Article

Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1=50% (GFPC 01-20 Study)

CLINICAL LUNG CANCER (2022)

Journal

CLINICAL LUNG CANCER

Volume 23, Issue 8, Pages E545-E549

Publisher

CIG MEDIA GROUP, LP

DOI: 10.1016/j.cllc.2022.09.002

Keywords

Immunotherapy; MET exon 14 skipping mutation; non-small cell lung cancer; oncogenic addiction; biomarker

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4

Not enough ratings

Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1=50% (GFPC 01-20 Study)

Journal

CLINICAL LUNG CANCER

Publisher

CIG MEDIA GROUP, LP

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1=50% (GFPC 01-20 Study)

Journal

CLINICAL LUNG CANCER

Publisher

CIG MEDIA GROUP, LP

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper